Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


03.02.2025

1 Acta Radiol
1 BJU Int
2 BMC Cancer
1 BMC Urol
4 BMJ Oncol
1 Clin Cancer Res
1 Curr Treat Options Oncol
1 Eur Urol
1 Int J Radiat Oncol Biol Phys
1 J Natl Cancer Inst
2 J Urol
1 Nat Rev Urol
1 Oncology
3 PLoS One
10 Prostate


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Radiol

  1. WEN X, Jiang CY, Jiang X, Chen Y, et al
    Comparative diagnostic performance of (68)Ga-PSMA-11 PET/CT and (68)Ga-PSMA-11 PET/MRI in detecting biochemical recurrent bone metastasis in prostate cancer: a systematic review and meta-analysis.
    Acta Radiol. 2025 Jan 26:2841851241307336. doi: 10.1177/02841851241307336.
    PubMed         Abstract available


    BJU Int

  2. GNANAPRAGASAM VJ, Keates A, Lophatananon A, Thankapannair V, et al
    The 5-year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer.
    BJU Int. 2025 Jan 29. doi: 10.1111/bju.16666.
    PubMed         Abstract available


    BMC Cancer

  3. SCHUMACHER O, Newton RU, Tang C, Chee R, et al
    Exercise medicine as adjunct therapy during RADIation for CAncer of the prostaTE to improve treatment efficacy - protocol for the ERADICATE study: a phase II randomised controlled trial.
    BMC Cancer. 2025;25:160.
    PubMed         Abstract available

  4. VAN DER STARRE CM, Bangma CH, Bijlsma MJ, van den Bergh ACM, et al
    External beam radiation therapy versus radical prostatectomy for high-risk prostate cancer: protocol of the RECOVER study.
    BMC Cancer. 2025;25:149.
    PubMed         Abstract available


    BMC Urol

  5. ZHANG Y, Zhou X, Xu R, Luo G, et al
    Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis.
    BMC Urol. 2025;25:17.
    PubMed         Abstract available


    BMJ Oncol

  6. FITZPATRICK P
    Consideration of initial steps to implementation of prostate cancer screening following the EU recommendation.
    BMJ Oncol. 2024;3:e000579.
    PubMed        

  7. LOMBE DC, Mwamba M, Simwinga M, Bond V, et al
    Defining national research priorities for prostate cancer in Zambia: using the Delphi process for comprehensive cancer policy setting in sub-Saharan Africa.
    BMJ Oncol. 2024;3:e000172.
    PubMed         Abstract available

  8. BROMLEY HL, Varughese M, Gilbert DC, Hoskin P, et al
    Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review.
    BMJ Oncol. 2024;3:e000198.
    PubMed         Abstract available

  9. ALI A, Elumalai T, Venkatesulu B, Hekman L, et al
    Tale of two zones: investigating the clinical outcomes and research gaps in peripheral and transition zone prostate cancer through a systematic review and meta-analysis.
    BMJ Oncol. 2024;3:e000193.
    PubMed         Abstract available


    Clin Cancer Res

  10. CHIU CL, Zhang D, Zhao H, Wei Y, et al
    Targeting AXL inhibits the growth and metastasis of prostate cancer in bone.
    Clin Cancer Res. 2025 Jan 29. doi: 10.1158/1078-0432.CCR-24-3028.
    PubMed         Abstract available


    Curr Treat Options Oncol

  11. SERRITELLA AV, Hussain M
    Correction to: Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy.
    Curr Treat Options Oncol. 2025 Jan 25. doi: 10.1007/s11864-025-01294.
    PubMed        


    Eur Urol

  12. MORGAN TM, Daignault-Newton S, Spratt DE, Dunn RL, et al
    Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial.
    Eur Urol. 2025;87:228-237.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  13. PATEL KR, Pra AD, Huang EP, Singh SA, et al
    The Determinants of Toxicity in the Treatment of Prostate Cancer with a Focal, Intraprostatic "Microboost".
    Int J Radiat Oncol Biol Phys. 2025 Jan 22:S0360-3016(25)00054.
    PubMed         Abstract available


    J Natl Cancer Inst

  14. TOSOIAN JJ
    Active surveillance for prostate cancer: How active is too active?
    J Natl Cancer Inst. 2025 Jan 27:djae342. doi: 10.1093.
    PubMed        


    J Urol

  15. KIM EH, Jing H, Utt KL, Vetter JM, et al
    An Artificial Intelligence Model Using Diffusion Basis Spectrum Imaging Metrics Accurately Predicts Clinically Significant Prostate Cancer.
    J Urol. 2025 Jan 27:101097JU0000000000004456. doi: 10.1097/JU.0000000000004456.
    PubMed         Abstract available

  16. LUGHEZZANI G, Fasulo V, Lazzeri M
    Letter: Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer.
    J Urol. 2025 Jan 24:101097JU0000000000004420. doi: 10.1097/JU.0000000000004420.
    PubMed        


    Nat Rev Urol

  17. GHARBIEH S, Mullin J, Jaffer A, Chia D, et al
    Epidemiology, diagnosis and treatment of anterior prostate cancer.
    Nat Rev Urol. 2025 Jan 28. doi: 10.1038/s41585-024-00992.
    PubMed         Abstract available


    Oncology

  18. GUI Q, Wang X, Wu D, Guo Y, et al
    Constructing and Validating Models for Predicting Gleason Grade Group Upgrading Following Radical Prostatectomy in Localized Prostate Cancer: A Comparison between Machine Learning Algorithms and Conventional Logistic Regression.
    Oncology. 2025 Jan 24:1-15. doi: 10.1159/000543492.
    PubMed         Abstract available


    PLoS One

  19. WILHELM ED, Dankert JT, Wiesehofer M, Wach S, et al
    xCT as a potential marker for neuroendocrine cells in high-risk prostate cancer and the relation to AL122023.1-miR-26a/30d/30e axis.
    PLoS One. 2025;20:e0318213.
    PubMed         Abstract available

  20. STAFFURTH JN, Sivell S, Baddeley E, Ahmedzai S, et al
    The impact of specialised gastroenterology services for pelvic radiation disease (PRD): Results from the prospective multi-centre EAGLE study.
    PLoS One. 2025;20:e0303356.
    PubMed         Abstract available

  21. XU W, Zhu G, Wang X, Yan X, et al
    Predicting the risk of bone metastases in patients with newly diagnosed prostate cancer - Development and validation of a nomogram model.
    PLoS One. 2025;20:e0318051.
    PubMed         Abstract available


    Prostate

  22. ORSINI A, Ferretti S, Porreca A, Castellan P, et al
    PI-RADS in Predicting csPCa: A Comparison Between Academic and Nonacademic Centers.
    Prostate. 2025;85:337-343.
    PubMed         Abstract available

  23. AYRANCI A, Caglar U, Yazili HB, Erdal FS, et al
    PSA Density and Lesion Volume: Key Factors in Avoiding Unnecessary Biopsies for PI-RADS 3 Lesions.
    Prostate. 2025;85:385-390.
    PubMed         Abstract available

  24. ODERDA M, Marquis A, Bertero L, Calleris G, et al
    Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging-Invisible Prostate Cancers: A Matched-Pair Analysis.
    Prostate. 2025;85:374-384.
    PubMed         Abstract available

  25. STANGL-KREMSER J, Ricaurte-Fajardo A, Huicochea Castellanos S, Martinez-Fundichely A, et al
    Baseline Imaging Derived Factors of Response Following [225Ac]Ac-J591 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Lesion Level Analysis.
    Prostate. 2025 Jan 23:e24853. doi: 10.1002/pros.24853.
    PubMed         Abstract available

  26. BESIROGLU H, Kadihasanoglu M
    The Safety and Efficacy of Targeted Alpha Therapy, Ac-225 Prostate-Specific Membrane Antigen, in Patients With Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
    Prostate. 2025 Jan 26:e24857. doi: 10.1002/pros.24857.
    PubMed         Abstract available

  27. CIRULLI GO, Stephens A, Chiarelli G, Finati M, et al
    Comparing PSA Screening Patterns and Their Role as Predictor of Prostate Cancer Diagnosis: Analysis of a Contemporary North American Cohort.
    Prostate. 2025 Jan 27:e24856. doi: 10.1002/pros.24856.
    PubMed         Abstract available

  28. BEATRICI E, De Carne F, Frego N, Moretto S, et al
    Optimizing Prostate Cancer Diagnostic Work-Up Through Micro-Ultrasound: Minimizing Unnecessary Procedures and Reducing Overdiagnoses.
    Prostate. 2025 Jan 28:e24862. doi: 10.1002/pros.24862.
    PubMed         Abstract available

  29. SHEN C, Chen Z, Hu FH, Wang W, et al
    Reassessing the Role of Low PSA in Prognosis Across Grades of Prostate Cancer: A Cohort Study.
    Prostate. 2025 Jan 29:e24860. doi: 10.1002/pros.24860.
    PubMed         Abstract available

  30. SUN Y, Zhu J, Zhong H, Zhang Z, et al
    Transcriptome-Wide Association Study Identified Novel Blood Tissue Gene Biomarkers for Prostate Cancer Risk.
    Prostate. 2025 Jan 29:e24859. doi: 10.1002/pros.24859.
    PubMed         Abstract available

  31. NISHIMOTO M, De Velasco MA, Yamamoto Y, Fujimoto S, et al
    Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration-Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate.
    Prostate. 2025 Jan 31:e24865. doi: 10.1002/pros.24865.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.